Skip to main content
Journal cover image

Clinical staging of prostate cancer: reproducibility and clarification of issues.

Publication ,  Journal Article
Campbell, T; Blasko, J; Crawford, ED; Forman, J; Hanks, G; Kuban, D; Montie, J; Moul, J; Pollack, A; Raghavan, D; Ray, P; Roach, M; Stone, N ...
Published in: Int J Cancer
June 20, 2001

The American Joint Committee on Cancer (AJCC) staging system for prostate cancer adopted in 1992 is based on tumor-node-metastasis (TNM) designations. It has been widely accepted for use in local and advanced disease. The purpose of this study was to assess reproducibility of staging among observers and to help clarify staging issues. Twelve prostate cancer cases were sent to 20 physicians with special expertise in prostate cancer including eight urologists, eight radiation oncologists, and four medical oncologists. Physicians were asked to assign a stage based on the 1992 AJCC clinical staging. The most frequently reported stage assigned to each case was taken to be the consensus. Agreement was the percentage of physicians who reported that particular stage. Seventy-five percent of the physicians responded. The overall agreement for assignment of T stage was 63.9%. Differences were found by specialty for inclusion of available information in designating a T stage. The overall agreement for N stage was 73.8%. The most common designation was Nx regardless of availability of a computed tomography scan. The overall agreement for M stage was 76.6%. Without a bone scan the most common designation was Mx regardless of Gleason grade or prostate-specific antigen (PSA). A frequent comment was that PSA was more indicative of disease extent than current clinical staging. The reproducibility of the 1992 clinical AJCC staging is poor even among experts in the field. This problem arises primarily from disagreement regarding which studies are included in assigning a stage. Some of these difficulties are addressed in the 1997 revision. However, the clinical staging does not address the true biological significance of disease in many instances.

Duke Scholars

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

June 20, 2001

Volume

96

Issue

3

Start / End Page

198 / 209

Location

United States

Related Subject Headings

  • Reproducibility of Results
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Campbell, T., Blasko, J., Crawford, E. D., Forman, J., Hanks, G., Kuban, D., … Vijayakumar, S. (2001). Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer, 96(3), 198–209. https://doi.org/10.1002/ijc.1017
Campbell, T., J. Blasko, E. D. Crawford, J. Forman, G. Hanks, D. Kuban, J. Montie, et al. “Clinical staging of prostate cancer: reproducibility and clarification of issues.Int J Cancer 96, no. 3 (June 20, 2001): 198–209. https://doi.org/10.1002/ijc.1017.
Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, et al. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer. 2001 Jun 20;96(3):198–209.
Campbell, T., et al. “Clinical staging of prostate cancer: reproducibility and clarification of issues.Int J Cancer, vol. 96, no. 3, June 2001, pp. 198–209. Pubmed, doi:10.1002/ijc.1017.
Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer. 2001 Jun 20;96(3):198–209.
Journal cover image

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

June 20, 2001

Volume

96

Issue

3

Start / End Page

198 / 209

Location

United States

Related Subject Headings

  • Reproducibility of Results
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis